Regeneron Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 03/22/2023
Regeneron Pharmaceuticals Inc Stock Forecast and Price Target
The average target price for Regeneron Pharmaceuticals Inc's stock set by nine renowned analysts in recent months is $782.00, representing a potential upside of approximately 2.92% from its last closing price if met by 2024. This estimation is based on a high estimate of $1023.00 and a low estimate of $595.00. If you want to invest in REGN stock, you might also want to take a look at how its competitors are doing.
2.92% Upside
Regeneron Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Regeneron Pharmaceuticals Inc's Price has seen an increase, rising from $311.34 to $942.21. This represents a growth of 202.63%. According to 22 major analysts, Regeneron Pharmaceuticals Inc's Fair Value will fall by 38.48% in the next year, reaching $579.64. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Fair Value will fall to $508.21– a 46.06% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$153.96 | $181.05 | 17.24% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$331.08 | $333.19 | 20.82% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$40.66 | $53.97 | 29.49% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$105.62 | $99.57 | 11.72% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$67.52 | $80.99 | 22.93% |
Regeneron Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Regeneron Pharmaceuticals Inc's Revenue has seen an increase, rising from $6.56B to $16.07B. This represents a growth of 145.09%. According to 20 major analysts, Regeneron Pharmaceuticals Inc's Revenue will fall by 22.68% in the next year, reaching $12.43B. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Revenue will fall to $11.25B– a 29.98% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
16
|
$302.66 | $323.74 | 7.71% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$166.35 | $209.70 | 23.23% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$39.62 | $60.73 | 46.39% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$190.34 | $244.18 | 31.87% |
| VTRS Stock Forecast | Viatris | Hold |
8
|
$9.44 | $13.70 | 43.01% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$222.34 | $280.69 | 32.68% |
Regeneron Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
Regeneron Pharmaceuticals Inc's Free Cash Flow has grown in the last two years, jumping from $2.00B to $6.53B – an increase of 226.40%. In the following year, 5 experts forecast that Regeneron Pharmaceuticals Inc's Free Cash Flow will decrease by 14.74%, to $5.57B. In 2030, professionals predict that Regeneron Pharmaceuticals Inc's Free Cash Flow will decrease by 20.88%, to $5.17B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$66.78 | $83.92 | 9.31% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$35.62 | $52.42 | 40.37% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$36.17 | $62.67 | 65.88% |
Regeneron Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Net Income for Regeneron Pharmaceuticals Inc has grown by 281.67%, going from $2.12B to $8.08B. According to 18 analysts, Regeneron Pharmaceuticals Inc's Net Income will fall by 35.07% in the next year, reaching $5.24B. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's Net Income will fall to $4.68B – a 42.02% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$127.30 | $163.67 | 28.83% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$18.91 | $37.00 | 34.85% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$21.25 | $0.00 | 38.82% |
Regeneron Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Regeneron Pharmaceuticals Inc's EBITDA has increased by 276.04%, going from $2.46B to $9.23B. 6 analysts predict Regeneron Pharmaceuticals Inc's EBITDA will decrease by 28.65% in the next year, reaching $6.59B. By 2030, professionals predict that Regeneron Pharmaceuticals Inc's EBITDA will decrease by 35.39%, to $5.97B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$14.91 | $73.38 | 27.43% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£179.50 | £3.79 | -97.36% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$40.28 | $79.67 | 93.64% |
Regeneron Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Regeneron Pharmaceuticals Inc's EBIT has grown, increasing from $2.25B to $8.95B – an increase of 298.52%. For the following year, the 5 analysts predict that Regeneron Pharmaceuticals Inc's EBIT will drop by 41.32%, reaching $5.25B. In 2030, the professionals' prediction is that REGN's EBIT will decrease by 50.53%, reaching $4.43B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$36.99 | $41.00 | 18.95% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$10.59 | $12.60 | 18.04% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$36.70 | $35.50 | -7.36% |
Regeneron Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Regeneron Pharmaceuticals Inc's EPS has seen an increase, rising from $24.67 to $74.66. This represents a growth of 202.63%. According to 22 major analysts, Regeneron Pharmaceuticals Inc's EPS will fall by 38.48% in the next year, reaching $45.93. Professionals believe that By 2030, Regeneron Pharmaceuticals Inc's EPS will fall to $40.27– a 46.06% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$71.18 | $195.43 | 122.67% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$245.62 | $170.08 | -28.75% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$61.15 | $104.00 | -6.79% |